September 18 – 22, 2015
Cavtat, Croatia
Ubiquitin and ubiquitin-like modifiers: From molecular mechanisms to human diseases
Contact: Boris Rodenko (VP Translational Drug Discovery) / Alfred Nijkerk (CEO)